NO330300B1 - Anvendelse av angiotensin II-antagonister for fremstilling av medikamenter for behandling av sykdom - Google Patents
Anvendelse av angiotensin II-antagonister for fremstilling av medikamenter for behandling av sykdom Download PDFInfo
- Publication number
- NO330300B1 NO330300B1 NO20026085A NO20026085A NO330300B1 NO 330300 B1 NO330300 B1 NO 330300B1 NO 20026085 A NO20026085 A NO 20026085A NO 20026085 A NO20026085 A NO 20026085A NO 330300 B1 NO330300 B1 NO 330300B1
- Authority
- NO
- Norway
- Prior art keywords
- angiotensin
- type
- headache
- migraine
- receptor antagonist
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 24
- 238000011282 treatment Methods 0.000 title claims description 22
- 239000003814 drug Substances 0.000 title claims description 19
- 229940079593 drug Drugs 0.000 title claims description 18
- 201000010099 disease Diseases 0.000 title description 4
- 238000004519 manufacturing process Methods 0.000 title description 3
- 229940123413 Angiotensin II antagonist Drugs 0.000 title 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 title 1
- 208000019695 Migraine disease Diseases 0.000 claims description 40
- GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 claims description 37
- 206010027599 migraine Diseases 0.000 claims description 37
- 208000001407 Vascular Headaches Diseases 0.000 claims description 24
- 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 claims description 23
- 229960004349 candesartan cilexetil Drugs 0.000 claims description 22
- 208000035475 disorder Diseases 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 10
- 239000002053 C09CA06 - Candesartan Substances 0.000 claims description 9
- 229960000932 candesartan Drugs 0.000 claims description 9
- 239000012453 solvate Substances 0.000 claims description 8
- 239000013543 active substance Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 206010020772 Hypertension Diseases 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 230000000069 prophylactic effect Effects 0.000 claims description 4
- 206010019233 Headaches Diseases 0.000 description 26
- 231100000869 headache Toxicity 0.000 description 23
- 208000024891 symptom Diseases 0.000 description 10
- 239000000902 placebo Substances 0.000 description 9
- 229940068196 placebo Drugs 0.000 description 9
- 230000000694 effects Effects 0.000 description 6
- 229940058087 atacand Drugs 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 102000005862 Angiotensin II Human genes 0.000 description 4
- 101800000733 Angiotensin-2 Proteins 0.000 description 4
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 4
- 229950006323 angiotensin ii Drugs 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000002464 receptor antagonist Substances 0.000 description 4
- 229940044551 receptor antagonist Drugs 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 206010028813 Nausea Diseases 0.000 description 3
- 206010034960 Photophobia Diseases 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 2
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 2
- 206010016059 Facial pain Diseases 0.000 description 2
- 208000027109 Headache disease Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010036313 Post-traumatic headache Diseases 0.000 description 2
- 206010043269 Tension headache Diseases 0.000 description 2
- 208000008548 Tension-Type Headache Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000012790 cranial neuralgia Diseases 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229960002198 irbesartan Drugs 0.000 description 2
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 241000252151 Amiidae Species 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000006561 Cluster Headache Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000025047 Non-histaminic angioedema Diseases 0.000 description 1
- 206010054956 Phonophobia Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 235000003407 Sigesbeckia orientalis Nutrition 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- HTQMVQVXFRQIKW-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 HTQMVQVXFRQIKW-UHFFFAOYSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000018912 cluster headache syndrome Diseases 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 1
- 229960004943 ergotamine Drugs 0.000 description 1
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 229940043274 prophylactic drug Drugs 0.000 description 1
- 230000001107 psychogenic effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 210000001994 temporal artery Anatomy 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Mattresses And Other Support Structures For Chairs And Beds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0002353A SE0002353D0 (sv) | 2000-06-22 | 2000-06-22 | New use |
| PCT/SE2001/001379 WO2001097807A1 (en) | 2000-06-22 | 2001-06-15 | New use of angiotensin ii antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20026085D0 NO20026085D0 (no) | 2002-12-18 |
| NO20026085L NO20026085L (no) | 2002-12-18 |
| NO330300B1 true NO330300B1 (no) | 2011-03-28 |
Family
ID=20280208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20026085A NO330300B1 (no) | 2000-06-22 | 2002-12-18 | Anvendelse av angiotensin II-antagonister for fremstilling av medikamenter for behandling av sykdom |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7872035B2 (zh) |
| EP (2) | EP1307192B1 (zh) |
| JP (1) | JP2003535897A (zh) |
| KR (1) | KR100692235B1 (zh) |
| CN (2) | CN1250218C (zh) |
| AT (1) | ATE318597T1 (zh) |
| AU (2) | AU2001274765B2 (zh) |
| BR (1) | BR0111900A (zh) |
| CA (1) | CA2411553A1 (zh) |
| DE (1) | DE60117541T2 (zh) |
| DK (1) | DK1307192T3 (zh) |
| ES (1) | ES2257416T3 (zh) |
| HK (1) | HK1053609A1 (zh) |
| IL (2) | IL153158A0 (zh) |
| MX (1) | MXPA02012574A (zh) |
| NO (1) | NO330300B1 (zh) |
| NZ (1) | NZ523048A (zh) |
| PT (1) | PT1307192E (zh) |
| SE (1) | SE0002353D0 (zh) |
| WO (1) | WO2001097807A1 (zh) |
| ZA (1) | ZA200209902B (zh) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2436361C (en) * | 2001-01-29 | 2010-11-02 | Takeda Chemical Industries, Ltd. | Angiotensin ii antagonistic compound for use as analgesic and antiinflammatory agent |
| US20050065094A1 (en) * | 2003-09-05 | 2005-03-24 | Boehringer Ingelheim International Gmbh | Use of telmisartan for the prevention and treatment of vascular headache |
| FR2892803B1 (fr) | 2005-10-28 | 2008-04-04 | Valeo Systemes Thermiques | Boite collectrice pour echangeur de chaleur, notamment pour evaporateur de climatisation, echangeur comportant une telle boite |
| JP5468420B2 (ja) * | 2010-03-04 | 2014-04-09 | 株式会社マキタ | 手持ち式切断工具 |
| WO2012135597A2 (en) * | 2011-03-30 | 2012-10-04 | The Johns Hopkins University | Novel, protective, anti-inflammatory receptor and its use in preservation of mitochondrial function, wound healing and repair |
| KR20130074808A (ko) | 2011-12-16 | 2013-07-05 | 한올바이오파마주식회사 | 스타틴계 지질저하제에 의한 근육계 부작용의 치료 또는 예방을 위한 로사르탄을 포함하는 약제학적 조성물 |
| TWI754772B (zh) * | 2017-09-06 | 2022-02-11 | 美商美國禮來大藥廠 | 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5196444A (en) * | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
| US5703110A (en) * | 1990-04-27 | 1997-12-30 | Takeda Chemical Industries, Ltd. | Benzimidazole derivatives, their production and use |
| US5241009A (en) | 1990-05-07 | 1993-08-31 | Kimberly-Clark Corporation | Polymeric composition containing carboxy nueutralized with lithium or potassium |
| CA2041763A1 (en) * | 1990-05-11 | 1991-11-12 | Sheih-Shung T. Chen | Microbial transformation process for antihypertensive products |
| US5128327A (en) * | 1991-03-25 | 1992-07-07 | Merck & Co., Inc. | Angiotensin II antagonists incorporating a nitrogen containing six membered ring heterocycle |
| US5177074A (en) | 1991-03-26 | 1993-01-05 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted thiophene or furan |
| US5214153A (en) * | 1992-04-23 | 1993-05-25 | Merck & Co., Inc. | Actinoplanes transformation process anti-hypertensive compound and method of use thereas |
-
2000
- 2000-06-22 SE SE0002353A patent/SE0002353D0/xx unknown
-
2001
- 2001-06-15 IL IL15315801A patent/IL153158A0/xx not_active IP Right Cessation
- 2001-06-15 DE DE60117541T patent/DE60117541T2/de not_active Expired - Lifetime
- 2001-06-15 AT AT01941408T patent/ATE318597T1/de active
- 2001-06-15 MX MXPA02012574A patent/MXPA02012574A/es active IP Right Grant
- 2001-06-15 KR KR1020027017396A patent/KR100692235B1/ko not_active IP Right Cessation
- 2001-06-15 NZ NZ523048A patent/NZ523048A/en not_active IP Right Cessation
- 2001-06-15 PT PT01941408T patent/PT1307192E/pt unknown
- 2001-06-15 CN CNB018142788A patent/CN1250218C/zh not_active Expired - Fee Related
- 2001-06-15 AU AU2001274765A patent/AU2001274765B2/en not_active Ceased
- 2001-06-15 CA CA002411553A patent/CA2411553A1/en not_active Abandoned
- 2001-06-15 BR BR0111900-1A patent/BR0111900A/pt not_active IP Right Cessation
- 2001-06-15 EP EP01941408A patent/EP1307192B1/en not_active Expired - Lifetime
- 2001-06-15 EP EP05028367A patent/EP1656940A1/en not_active Withdrawn
- 2001-06-15 WO PCT/SE2001/001379 patent/WO2001097807A1/en active IP Right Grant
- 2001-06-15 ES ES01941408T patent/ES2257416T3/es not_active Expired - Lifetime
- 2001-06-15 AU AU7476501A patent/AU7476501A/xx active Pending
- 2001-06-15 DK DK01941408T patent/DK1307192T3/da active
- 2001-06-15 JP JP2002503291A patent/JP2003535897A/ja active Pending
- 2001-06-15 CN CNA2006100088164A patent/CN1846697A/zh active Pending
- 2001-06-15 US US10/311,760 patent/US7872035B2/en not_active Expired - Fee Related
-
2002
- 2002-11-28 IL IL153158A patent/IL153158A/en unknown
- 2002-12-05 ZA ZA200209902A patent/ZA200209902B/en unknown
- 2002-12-18 NO NO20026085A patent/NO330300B1/no not_active IP Right Cessation
-
2003
- 2003-08-19 HK HK03105920A patent/HK1053609A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| SE0002353D0 (sv) | 2000-06-22 |
| AU7476501A (en) | 2002-01-02 |
| ATE318597T1 (de) | 2006-03-15 |
| AU2001274765B2 (en) | 2005-08-18 |
| KR20030019444A (ko) | 2003-03-06 |
| US20040092563A1 (en) | 2004-05-13 |
| ES2257416T3 (es) | 2006-08-01 |
| DE60117541T2 (de) | 2006-09-14 |
| KR100692235B1 (ko) | 2007-03-09 |
| MXPA02012574A (es) | 2003-04-10 |
| ZA200209902B (en) | 2004-03-05 |
| EP1307192B1 (en) | 2006-03-01 |
| WO2001097807A1 (en) | 2001-12-27 |
| CN1447693A (zh) | 2003-10-08 |
| CN1846697A (zh) | 2006-10-18 |
| US7872035B2 (en) | 2011-01-18 |
| IL153158A (en) | 2008-03-20 |
| PT1307192E (pt) | 2006-06-30 |
| DK1307192T3 (da) | 2006-06-12 |
| NO20026085D0 (no) | 2002-12-18 |
| CA2411553A1 (en) | 2001-12-27 |
| EP1307192A1 (en) | 2003-05-07 |
| JP2003535897A (ja) | 2003-12-02 |
| CN1250218C (zh) | 2006-04-12 |
| BR0111900A (pt) | 2003-05-13 |
| EP1656940A1 (en) | 2006-05-17 |
| NO20026085L (no) | 2002-12-18 |
| IL153158A0 (en) | 2003-06-24 |
| HK1053609A1 (en) | 2003-10-31 |
| NZ523048A (en) | 2004-09-24 |
| DE60117541D1 (de) | 2006-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL153233A (en) | Extruded rubber structures for reinforcing internal spring assemblies and mattresses | |
| US20230115611A1 (en) | Treatment of pain and vasoconstriction | |
| KR100567154B1 (ko) | 트라마돌을 함유하는 약제학적 배합물 | |
| NO330300B1 (no) | Anvendelse av angiotensin II-antagonister for fremstilling av medikamenter for behandling av sykdom | |
| Parkes | Adverse effects of antiparkinsonian drugs | |
| US20180221380A1 (en) | Use of 5H-Dibenz/b,f/Azepine-5-Carboxamide Derivatives for Treating Fibromyalgia | |
| Macfarlane et al. | NSAIDs, antihypertensive agents and loss of blood pressure control. | |
| AU2001274765A1 (en) | New use of angiotensin II antagonists | |
| CA2866494A1 (en) | Compounds, compositions, and uses thereof for treatment of menopausal symptoms and menopausal hot flashes | |
| US20050043407A1 (en) | Pharmaceutical composition for the prevention and treatment of addiction in a mammal | |
| Kadri et al. | Efficacy and safety of clonazepam in refractory neurally mediated syncope | |
| RU2481124C1 (ru) | Фармацевтическая комбинация из аторвастатина и ницерголина для профилактики или лечения нарушений мозгового кровообращения | |
| WO2023150336A1 (en) | Methods of treating complex regional pain syndrome | |
| AU2005234678A1 (en) | New use of angiotensin II antagonists | |
| Wilson et al. | New drugs for the treatment of hypertension: where do they fit? | |
| Williams | Prevalence of diabetic neuropathy | |
| Rogstad | A comparison of lisinopril and nifedipine in the treatment of mild to moderate hypertension: a multicentre study | |
| Piñol et al. | Efficacy and safety of nitrendipine in the outpatient treatment of mild-to-moderate hypertension | |
| Vardi et al. | Cardiovascular effects of oral pharmacotherapy in erectile dysfunction | |
| COVER | Moving' | |
| Pickard | Section II: Reviews Antihypertensive Drugs In Aircrew |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |